Abingdon Health plc (AIM: ABDX) has provided an update on its partnership with 4TEEN4 Pharmaceuticals GmbH, focused on the co-development of a companion diagnostic for a potentially life-saving shock therapy.
Abingdon Health plc (AIM: ABDX) $2.5m Contract for clinical self-test development
$2.5m Contract Award for development of clinical self-test
Abingdon Health plc (AIM: ABDX) c.US$2m multiplex diagnostic test contract win
c.US$2m multiplex diagnostic test contract win Development, scale-up and technical transfer for a semi-quantitative, multiplex lateral flow test system
Abingdon Health plc (AIM: ABDX) Trading update
Revenue for FY25 in line with market expectations of £8.6m Continued strong revenue growth anticipated in FY26
Abingdon Health plc (AIM: ABDX) c. US$2.5m companion diagnostic test contract win
c. US$2.5m companion diagnostic test contract win Full CDMO service contract for development, scale-up, technical transfer, manufacture and full regulatory support
Abingdon Health PLC (AIM:ABDX) Funding award to develop test for malaria parasite
Point-of-care rapid diagnostic test for Plasmodium vivax infection to be developed for in-field testing
Abingdon Health PLC (AIM:ABDX) Appointment of Chief Financial Officer
York, U.K. 19 December 2024: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract research (CRO) and contract development and manufacturing organisation (CDMO), announces the appointment of Tom Hayes as